Can you take Cagrilintide and Exenatide together?

There is no specific, well-documented interaction rule for combining Cagrilintide and Exenatide in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, Cagrilintide or Exenatide?

Cagrilintide is currently investigational (in trials) and Exenatide is fda-approved. "Better researched" depends on your research goal — review each profile's cited sources.

GLP-1 & Metabolic · Comparison

Cagrilintide vs Exenatide

Q: What is the difference between Cagrilintide and Exenatide?

Cagrilintide: Long-acting amylin/CGRP receptor co-agonist developed by Novo Nordisk. Reduces food intake and body weight via central satiety pathways distinct from the GLP-1 pathway. In the CagriSema combination trial with semaglutide, the combination achieved up to ~25% weight reduction — substantially greater than either agent alone. Exenatide: First GLP-1 receptor agonist approved for clinical use (2005), derived from the Gila monster venom peptide exendin-4. Available as twice-daily immediate-release (Byetta) and once-weekly extended-release (Bydureon BCise) formulations. Established the GLP-1 agonist drug class and provided the foundational clinical evidence for cardiovascular and metabolic benefits. Both are in the GLP-1 & Metabolic category but differ in mechanism, dosing, and research evidence — see the full comparison.

A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

Cagrilintide

Investigational (in trials)

Long-acting amylin/CGRP receptor co-agonist developed by Novo Nordisk. Reduces food intake and body weight via central satiety pathways distinct from the GLP-1 pathway. In the CagriSema combination trial with semaglutide, the combination achieved up to ~25% weight reduction — substantially greater than either agent alone.

Full profile

Exenatide

FDA-approved

First GLP-1 receptor agonist approved for clinical use (2005), derived from the Gila monster venom peptide exendin-4. Available as twice-daily immediate-release (Byetta) and once-weekly extended-release (Bydureon BCise) formulations. Established the GLP-1 agonist drug class and provided the foundational clinical evidence for cardiovascular and metabolic benefits.

Full profile

	Cagrilintide	Exenatide
Category	GLP-1 & Metabolic	GLP-1 & Metabolic
Also known as	AM833, amylin analogue, CagriSema partner	Byetta, Bydureon, AC2993, exendin-4
Evidence	Investigational (in trials)	FDA-approved
Dosing range	0.3mg–2.4mg mg, once weekly subcutaneous	5mcg–2mg (weekly ER) mcg, Twice daily (immediate-release) or once weekly (extended-release)
Administration	Subcutaneous injection	Subcutaneous injection
Key side effects	Nausea, Vomiting, Injection site reactions, Decreased appetite	Nausea (most common, especially initial weeks), Vomiting, Diarrhea, Injection site nodules (extended-release formulation)
Cited sources	2 references	2 references

Key differences

Evidence level differs: Cagrilintide is investigational (in trials), while Exenatide is fda-approved.
Dosing units differ: Cagrilintide is dosed in mg, Exenatide in mcg — they operate at different scales.
Frequency: Cagrilintide is typically once weekly subcutaneous; Exenatide is Twice daily (immediate-release) or once weekly (extended-release).

How each works

Cagrilintide

Cagrilintide activates amylin receptors (RAMP/CTR complexes) in the area postrema and hypothalamus, reducing food intake and slowing gastric emptying through mechanisms independent of GLP-1 signaling. This non-overlapping pathway allows combination with semaglutide without compounding GI side effects. Phase 2 CagriSema data showed 15–25% weight loss at 32 weeks, supporting the complementary mechanism hypothesis.

Exenatide

Exenatide was identified from Gila monster (Heloderma suspectum) venom as exendin-4, a peptide with ~53% homology to human GLP-1 but with DPP-4 resistance enabling longer activity. Clinical trials demonstrated HbA1c reductions of 0.8–1.0%, weight loss of 2–4kg, and cardiovascular safety (EXSCEL trial showed non-inferiority). The extended-release microsphere formulation achieved comparable efficacy with once-weekly dosing.

Read the full Cagrilintide profile Read the full Exenatide profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.